Document Detail


CA-125 response patterns in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD).
MedLine Citation:
PMID:  20130507     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION:: In recurrent ovarian cancer, CA-125 could be the only objective response criteria. This study analyzes response patterns regarding CA-125 in responders versus nonresponders and determines whether a specific cutoff value for CA-125 could predict clinical response, compared with response evaluation criteria in solid tumors, in patients receiving pegylated liposomal doxorubicin (PLD). METHODS:: Sixty-eight patients were identified, 78% were platinum resistant. Relative changes in CA-125 values were calculated, and response was defined as higher than 50% reduction in CA-125 from baseline. Receiver operating characteristic (ROC) curves were constructed based on CA-125 value after the first cycle of PLD to evaluate the most precise cutoff point for the decision model predicting response. RESULTS:: Fifty-three patients were assessable for response: 16 patients responded and 37 did not; the median increase of CA-125 was 0.20 (-63; 312) and 52 (-29; 620), respectively. Our ROC curve generated a cutoff value with a sensitivity of 35% (positive test, the proportion of patients who will not respond) and a predictive positive value of 80%. According to the predictive positive value, 20% of the responder patients will be identified as nonresponders; P = 0.025. CONCLUSIONS:: Our ROC analysis did not demonstrate any reliable CA-125 cutoff on response. Discontinuation of the therapy before cycle 3 may exclude some patients who will benefit from PLD.
Authors:
Ana Oaknin; Pilar Barretina; Xavier P?rez; Laura Jimenez; Montserrat Velasco; Maria Alsina; Joan Brunet; Josep Ramon Germ?; Miguel Beltran
Related Documents :
20471887 - Serum angiopoietin-1 level is increased in patients with behçet's disease.
22072267 - Changes in listing plane thickness caused by vestibular schwannoma: a parameter for eva...
22039167 - Level of agreement of the 1987 acr and 2010 acr/eular rheumatoid arthritis classificati...
795797 - Problems with beaded fluorescence pattern in fta-abs test.
17459287 - Acetylator phenotype in iraqi patients with atopic dermatitis.
19958947 - Does failure to perform prophylactic level vi node dissection leave persistent disease ...
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society     Volume:  20     ISSN:  1525-1438     ISO Abbreviation:  Int. J. Gynecol. Cancer     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-02-04     Completed Date:  2010-04-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111626     Medline TA:  Int J Gynecol Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  87-91     Citation Subset:  IM    
Affiliation:
Gynecology Cancer Unit, Oncology Department, Vall d'Hebron University Hospital, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain. amoaknin@vhebron.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antibiotics, Antineoplastic / administration & dosage,  chemistry
Biomarkers, Pharmacological / blood,  metabolism
CA-125 Antigen / blood*
Cystadenocarcinoma, Serous / blood*,  diagnosis,  drug therapy*
Doxorubicin / administration & dosage*,  chemistry
Female
Humans
Liposomes
Middle Aged
Ovarian Neoplasms / blood*,  diagnosis,  drug therapy*
Polyethylene Glycols / chemistry
Predictive Value of Tests
Prognosis
ROC Curve
Recurrence
Sensitivity and Specificity
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Biomarkers, Pharmacological; 0/CA-125 Antigen; 0/Liposomes; 0/Polyethylene Glycols; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient ou...
Next Document:  Expression of hCG and GnRHs and their receptors in endometrial carcinoma and hyperplasia.